Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antifungal drug
Fosmanogepix
Другие языки:

    Fosmanogepix

    Подписчиков: 0, рейтинг: 0
    Fosmanogepix
    Fosmanogepix.svg
    Clinical data
    Other names APX001, APX-001
    ATC code
    • None
    Legal status
    Legal status
    • Investigational
    Identifiers
    • [2-Amino-3-(3-{4-[(2-pyridinyloxy)methyl]benzyl}-1,2-oxazol-5-yl)-1-pyridiniumyl]methyl hydrogen phosphate
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C22H21N4O6P
    Molar mass 468.406 g·mol−1
    3D model (JSmol)
    • c1ccnc(c1)OCc2ccc(cc2)Cc3cc(on3)c4ccc[n+](c4N)COP(=O)(O)[O-]
    • InChI=1S/C22H21N4O6P/c23-22-19(4-3-11-26(22)15-31-33(27,28)29)20-13-18(25-32-20)12-16-6-8-17(9-7-16)14-30-21-5-1-2-10-24-21/h1-11,13,23H,12,14-15H2,(H2,27,28,29)
    • Key:JQONJQKKVAHONF-UHFFFAOYSA-N

    Fosmanogepix is an experimental antifungal drug being developed by Pfizer. It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis.

    Fosmanogepix is a prodrug and is converted into the active drug form, manogepix, after administration. Manogepix targets the inositol acyltransferase Gwt1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1), an enzyme in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway. Inhibiting this enzyme prevents the fungi from producing certain proteins essential to its life cycle. This mechanism of action is novel; therefore, if approved, fosmanogepix would become a first-in-class medication.



    Новое сообщение